PubMed Health⌕ Search

PubMed · 6352032

Evolution and the cardiac patient.

Abstract

These essays have traced the evolution of three great convective systems of the body: ventilation, circulation and excretion. We have seen how the ventilatory system evolved with an inherent susceptibility to flooding, how the kidney came to need an enormous blood flow and how a high blood pressure grew out of the explosive demands of muscular activity. Success and survival in the animal kingdom have overwhelmingly depended on physical mobility and strength. To ensure this the body makes use of the neuro-endocrine defence reaction which is also life-saving in injury. The reaction favours the retention of water and salt by directing blood away from the kidney and by endocrine activity. When the output of the diseased heart decreases, the body reacts in the way for which nature has programmed it. It cannot distinguish. But now the neuro-endocrine response persists. But now the neuro-endocrine response persists. Over weeks or months or years the retention of saline threatens the cardiac patient with drowning in his own juice. And every hour of the day and night be is running for his life.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Harris. 1983. Evolution and the cardiac patient.. https://doi.org/10.1093/cvr%2F17.8.437

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗